Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OSBP | P22059 | 6/20 | 0.94 |
| ▸ | RORC | P51449 | 5/20 | 0.94 |
| ▸ | OSBP2 | Q969R2 | 3/20 | 0.94 |
| ▸ | USP2 | O75604 | 1/20 | 0.94 |
| ▸ | LMNA | P02545 | 1/20 | 0.94 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.94 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.94 |
| ▸ | GRIN1 | Q05586 | 6/20 | 0.87 |
| ▸ | GRIN2A | Q12879 | 6/20 | 0.87 |
| ▸ | NR1H3 | Q13133 | 7/20 | 0.82 |
| ▸ | DHCR24 | Q15392 | 1/20 | 0.76 |
| ▸ | CRYAB | P02511 | 1/20 | 0.76 |
| ▸ | HMGCR | P04035 | 1/20 | 0.76 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.76 |
| ▸ | ITGAV | P06756 | 1/20 | 0.76 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.76 |
| ▸ | NPC1L1 | Q9UHC9 | 1/20 | 0.76 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.75 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.72 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cholesterol SCHEMBL21681224 | 1.00 | OSBP (0.94) | OSBPRORCOSBP2USP2LMNA | |
| Cholesterol SCHEMBL454869 | 1.00 | OSBP (0.94) | OSBPRORCOSBP2USP2LMNA | |
| Cholesterol SCHEMBL21707472 | 0.97 | OSBP (1.00) | OSBPRORCOSBP2USP2LMNA | |
| Cholesterol SCHEMBL21447271 | 0.97 | OSBP (1.00) | OSBPRORCOSBP2USP2LMNA | |
| Cholesterol SCHEMBL22095727 | 0.97 | OSBP (1.00) | OSBPRORCOSBP2USP2LMNA | |
| Cholesterol SCHEMBL23761109 | 0.97 | OSBP (1.00) | OSBPRORCOSBP2USP2LMNA | |
| Cholesterol SCHEMBL22225160 | 0.97 | OSBP (1.00) | OSBPRORCOSBP2USP2LMNA | |
| Cholesterol SCHEMBL23579652 | 0.97 | OSBP (1.00) | OSBPRORCOSBP2USP2LMNA | |
| Cholesterol SCHEMBL23365796 | 0.97 | OSBP (1.00) | OSBPRORCOSBP2USP2LMNA | |
| Cholesterol SCHEMBL21445079 | 0.97 | OSBP (1.00) | OSBPRORCOSBP2USP2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10087445-B2 | Modifications for antisense compounds | INTEGRATED DNA TECHNOLOGIES, INC. (US) | 2018-10-02 | — | — | US | disclosed |
| EP-2896696-B1 | Modifications for antisense compounds | INTEGRATED DNA TECH INC (US) | 2017-12-27 | — | — | EP | disclosed |
| US-20170204412-A1 | Modifications for Antisense Compounds | INTEGRATED DNA TECHNOLOGIES, INC. | 2017-07-20 | — | — | US | disclosed |
| US-9506059-B2 | Modifications for antisense compounds | INTEGRATED DNA TECHNOLOGIES, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-9506057-B2 | Modifications for antisense compounds | INTEGRATED DNA TECHNOLOGIES, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| EP-2959000-A1 | MODIFICATIONS FOR ANTISENSE COMPOUNDS | Integrated DNA Technologies Inc. (US) | 2015-12-30 | — | — | EP | disclosed |
| EP-2896696-A2 | Modifications for antisense compounds | INTEGRATED DNA TECHNOLOGIES, INC. (US) | 2015-07-22 | — | — | EP | disclosed |
| EP-2614149-B1 | MODIFICATIONS FOR ANTISENSE COMPOUNDS | INTEGRATED DNA TECH INC (US) | 2015-04-08 | — | — | EP | disclosed |
| US-20150011744-A1 | Modifications for Antisense Compounds | INTEGRATED DNA TECHNOLOGIES, INC. | 2015-01-08 | — | — | US | disclosed |
| WO-2014130945-A1 | MODIFICATIONS FOR ANTISENSE COMPOUNDS | INTEGRATED DNA TECHNOLOGIES, INC. (US) | 2014-08-28 | — | — | WO | disclosed |
| US-20130236967-A1 | Modifications for Antisense Compounds | INTEGRATED DNA TECHNOLOGIES, INC. (US) | 2013-09-12 | — | — | US | disclosed |
| EP-2614149-A1 | MODIFICATIONS FOR ANTISENSE COMPOUNDS | Integrated Dna Technologies, Inc. (US) | 2013-07-17 | — | — | EP | disclosed |
| US-20120108799-A1 | Modifications for Antisense Compounds | INTEGRATED DNA TECHNOLOGIES, INC. (US) | 2012-05-03 | — | — | US | disclosed |
| WO-2012033848-A1 | MODIFICATIONS FOR ANTISENSE COMPOUNDS | INTEGRATED DNA TECHNOLOGIES, INC. (US) | 2012-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108799-A1 | Modifications for Antisense Compounds | TRDMT1, NSUN3, NSUN2 | OSBP 1058/4885RORC 4214/4885OSBP2 588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.